{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:51:46Z","timestamp":1793400706696,"version":"4.5.0"},"reference-count":39,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Cyclin-dependent kinase (CDK) 4\/6 inhibitors have become a cornerstone in the treatment of hormone receptor-positive (HR+), and human epidermal growth factor receptor 2-negative (HER2-) breast cancer, demonstrating significant efficacy in both early and metastatic stages. However, despite their clinical benefits, emerging evidence from health databases, real-world studies, and case reports highlight potential cardiovascular risks, including QTc prolongation and thrombosis. This review aims to comprehensively evaluate the cardiovascular safety profiles of the three FDA-approved CDK4\/6 inhibitors\u2014palbociclib, ribociclib, and abemaciclib\u2014in patients with HR+\/HER2- advanced breast cancer. Specifically, it compares the risks of QTc prolongation and thrombosis associated with these agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data source<\/jats:title>\n                    <jats:p>A literature search was conducted using PubMed, ClinicalTrials.gov, and manual searches of relevant articles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection<\/jats:title>\n                    <jats:p>Studies included in this review were those that reported CDK4\/6 inhibitor cardiovascular outcomes, specifically QTc prolongation and thrombosis, in patients with advanced breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The review highlights significant differences in the cardiovascular safety profiles of CDK4\/6 inhibitors. Ribociclib is associated with the highest risk of QTc prolongation, with incidence rates ranging from 4.5% to 13.3% in RCTs, while palbociclib demonstrates a more favorable profile, with QTc prolongation reported in less than 1% of cases. Abemaciclib, although not linked to QTc prolongation, has the highest reported incidence of thrombosis, ranging from 2.0% to 4.9% in RCTs. Real-world data revealed thrombosis incidence rates as high as 17% among patients treated with CDK4\/6 inhibitors. Thus, future research must ascertain the cardiovascular safety profiles of different CDK4\/6 inhibitors and develop effective cardiovascular toxicity prevention strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251368239","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T06:45:52Z","timestamp":1755672352000},"page":"529-537","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiovascular safety of CDK4\/6 inhibitors in advance breast cancer: Assessing risks of QTc prolongation and thrombosis"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0171-7391","authenticated-orcid":false,"given":"Alaa","family":"Shahbar","sequence":"first","affiliation":[{"name":"Umm Al-Qura University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkae078"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2181338"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.693104"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14630"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02742"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02514"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12466"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00382-1"},{"key":"e_1_3_2_10_2","first-page":"3481","article-title":"Palbociclib improves cardiac dysfunction in diabetic cardiomyopathy by regulating Rb phosphorylation","volume":"11","author":"Wang Z","year":"2019","unstructured":"Wang Z, Li J, Wang Y, et al. Palbociclib improves cardiac dysfunction in diabetic cardiomyopathy by regulating Rb phosphorylation. Am J Transl Res 2019; 11: 3481\u20133489.","journal-title":"Am J Transl Res"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.638895"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114663"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.353"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911149"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3032"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30292-4"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903765"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02392"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0305"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00613-0"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505270"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02554"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30642-2"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7585"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.4782"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6155"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920963925"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000589"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13684"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy300.008"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2411309"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.029361"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13590"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34367"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14630"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S353584"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-022-02031-0"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251368239","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251368239","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251368239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:31:34Z","timestamp":1777689094000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251368239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1177\/10781552251368239"],"URL":"https:\/\/doi.org\/10.1177\/10781552251368239","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]}}}